Phoenix, AZ (Uptick Newswire – December 18, 2017) – Uptick Newswire is the sole producer of the Uptick Network “Stock Day” Podcast and after airing back in January 2016 CEO and host Everett Jolly has interviewed hundreds of CEO’s within the micro-cap publicly traded sector of the market bringing important updates to the investor community. Everett Jolly recently asked this Company to give an update on Stock Day because a lot has gone on in 2017 that has been exceptionally valuable to the bioscience industry.
Mr. Jolly warmly welcomes back Chris Bunka, CEO of Lexaria Biosciences, Corp. (OTCQB:LXRP) (“Lexaria” or the “Company”) and to start off the interview Mr. Bunka overviewed the Company’s patented technology in the biosciences industry and the benefits behind the substances related to the Company patents. He discussed the patent allowance, the expectations of this allowance, the additional patent claims and how valuable this move was for the Company. Mr. Jolly asked questions about the dramatic change in the stock price and the value of the Company and Mr. Bunka continued by answering these questions with his confidence in the Company patents and discussed the potential power that the Company holds with these patents. Mr. Bunka unveiled the metrics behind the most recent, final granting of a patent announced in December 13th press release and he stressed the potential of the patent in the medical industry.
In a final closing statement CEO Mr. Chris Bunka adds, “By no means should anyone think that the best is behind us, the best is absolutely still to come. We are working on a number of different initiatives, products, R&D science, patents, partners, commercial things and I think 2018 is going to make 2017 look boring in comparison.”
To listen to the full interview please click here or the following link: https://upticknewswire.com/featured-interview-ceo-chris-bunka-of-lexaria-bioscience-corp-otcqb-lxrp-3/
About Uptick Newswire and the “Stock Day Podcast”
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix Arizona with its new host Kathryn Donnelly.
Investors Hangout is a proud sponsor of Stock Day and Uptick Newswire encourages listeners to visit Lexeria’s message board on: https://investorshangout.com/Lexaria-Bioscience-Corp-LXRP-63966/
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional stock warrants or stock options will be exercised. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements; or that results from any studies will be favorable or in any way support future business activities of any kind. Scientific R&D is often unpredictable and unanticipated results could emerge from any study and have a material impact. There is no assurance that any planned corporate activity, scientific study, R&D, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria Energy Foods, Ambarii, DehydraTECHTM technology and ViPovaTM products are not intended to diagnose, treat, cure or prevent any disease.
Source: Uptick Newswire